Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Fineline Cube Jan 19, 2026
Policy / Regulatory

China’s Commerce Minister Meets with Global Pharma Leaders to Discuss Innovation Cooperation

Fineline Cube Mar 25, 2024

China’s Minister of Commerce, Wang Wentao, convened a high-level meeting with top executives from the...

Company Drug

Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU

Fineline Cube Mar 25, 2024

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary...

Company Deals

OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development

Fineline Cube Mar 25, 2024

OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...

Company Drug

Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs

Fineline Cube Mar 25, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Medical Device

Jenscare Scientific Completes Enrollment in Clinical Study for Mitral Valve Repair System

Fineline Cube Mar 25, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in...

Company Deals Digital

Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics

Fineline Cube Mar 25, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into...

Company Deals

Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments

Fineline Cube Mar 25, 2024

Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China,...

Company Deals Drug

Joincare Pharmaceuticals Secures Rights to Bayer’s Respiratory Drug in China

Fineline Cube Mar 25, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...

Company Deals

AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China

Fineline Cube Mar 25, 2024

AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous...

Company Deals

Sino Biological Partners with Rapid Novor to Market mAb Sequencing Services Across Asia

Fineline Cube Mar 22, 2024

Sino Biological Inc. (SHE: 301047), a leading supplier of reagents based in China, has announced...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase III Trial for Atopic Dermatitis Treatment

Fineline Cube Mar 22, 2024

Lynk Pharmaceuticals Co., Ltd, based in China, has announced the dosing of the first patient...

Company Drug

HutchMed Launches Phase II/III Study for Sovleplenib in Autoimmune Hemolytic Anemia

Fineline Cube Mar 22, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of the Phase II/III...

Company Drug

NeuExcell Therapeutics Doses First Patient in Groundbreaking Clinical Trial for NeuroD1 Gene Therapy

Fineline Cube Mar 22, 2024

NeuExcell Therapeutics, a Shanghai-based developer of in vivo neural regenerative therapies, has announced the first...

Company Deals

Astra Biotech Raises Tens of Millions in Pre-Series B Funding to Expand Diagnostic Capabilities

Fineline Cube Mar 22, 2024

Astra Biotech, a developer of single molecule immunodiagnostic technology based in Suzhou, has reportedly raised...

Company Deals

Horimed Secures Tens of Millions in Financing to Advance OCT Imaging Technologies

Fineline Cube Mar 22, 2024

Horimed, a Tianjin-based manufacturer of OCT imaging equipment, has reportedly raised “tens of millions” of...

Company Deals

Beijing Varnotech Biopharm Secures RMB 600 Million in Series B Funding for Vaccine Development

Fineline Cube Mar 22, 2024

Beijing Varnotech Biopharm Ltd, a China-based specialist in human vaccines, has successfully raised RMB 600...

Company Deals

PoreSpect Secures Tens of Millions in Angel Funding Led by Forcefield Ventures

Fineline Cube Mar 22, 2024

PoreSpect, a Guangdong-based manufacturer of devices and consumables, has reportedly secured “tens of millions” of...

Company Medical Device

Intuitive Surgical’s Ion Robotic System Gains Regulatory Approval in China

Fineline Cube Mar 22, 2024

Intuitive Surgical (NASDAQ: ISRG), a leading medical robotics firm based in the US, has announced...

Company

Henlius Biotech Posts 67.8% YOY Revenue Growth and First Annual Profit in 2023 Financials

Fineline Cube Mar 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) has released its financial results for 2023, reporting revenues...

Company

Bayer Eliminates C-Level Roles in Restructuring Efforts to Boost Profitability

Fineline Cube Mar 22, 2024

Germany’s Bayer (ETR: BAYN) has taken significant steps in its restructuring efforts by eliminating 8...

Posts pagination

1 … 330 331 332 … 611

Recent updates

  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.